Skip to main content
Clinical Trials/NCT01596283
NCT01596283
Completed
Phase 3

A Prospective Randomized Controlled Clinical Trial of Standard Compared to Goal-directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection

Memorial Sloan Kettering Cancer Center1 site in 1 country135 target enrollmentApril 2012
ConditionsLiver Cancer

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Liver Cancer
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
135
Locations
1
Primary Endpoint
Postoperative Complications
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to help us learn what is the best amount of fluid to administer to patients during liver surgery. Patients will receive either an amount for this surgery based on weight, blood pressure, heart rate and urine output or an amount guided by a computerized system (FloTrac) that helps doctors know how much fluid each patient needs. The FloTrac calculates the amount of fluid patients needs on a minute-to-minute basis, based on real time information like blood pressure, pulse and the ability of the heart and blood vessels to maintain normal vital signs.

Registry
clinicaltrials.gov
Start Date
April 2012
End Date
May 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults (18 years old or greater) who are able to provide informed consent.
  • Patients who undergo an open, elective liver resection. Including those initially approached laparoscopically but converted to an open resection and those undergoing additional procedures.

Exclusion Criteria

  • Active coronary disease.
  • Patients with a history of coronary disease will be eligible if they have had a cardiac stress study showing no reversible ischemia and normal LV function within 3 months of operation.
  • Active symptomatic cerebrovascular disease.
  • Active congestive heart failure and ejection fraction \<35%.
  • Active severe restrictive or obstructive pulmonary disease and resting SpO2 \<90%.
  • Active renal dysfunction (Cr \>1.8)
  • Abnormal coagulation parameters (INR \> 1.8 not on Coumadin, or platelet count \< 100,000 per mcL)
  • Presence of active infection including HIV
  • Patients with active atrial fibrillation or flutter.
  • Preoperative hypoalbuminemia (Albumin \< 2g/dl).

Outcomes

Primary Outcomes

Postoperative Complications

Time Frame: 30 days post procedure

The incidence of overall 30-day postoperative complications will be recorded. These are defined in the MSKCC Adverse Events Program and organized by categories reflecting organ systems and further subdivided into specific complications within those and graded.

Secondary Outcomes

  • Total Volume of Fluid Used Postoperatively(Postoperatively for the total admission time, up to 8 days)
  • Total Volume of Fluid Used Perioperatively(Up to the first 72 hours postoperatively)
  • Postoperative Length of Stay(Postoperatively for the total admission time, up to 8 days)
  • Low Cardiac Output Time(Up to the first 24 postoperative hours)

Study Sites (1)

Loading locations...

Similar Trials